Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 10 studies | 23% ± 8% | |
GABAergic neuron | 7 studies | 41% ± 21% | |
astrocyte | 7 studies | 31% ± 17% | |
glutamatergic neuron | 7 studies | 45% ± 24% | |
oligodendrocyte | 7 studies | 29% ± 11% | |
oligodendrocyte precursor cell | 7 studies | 27% ± 10% | |
macrophage | 5 studies | 18% ± 3% | |
microglial cell | 4 studies | 21% ± 3% | |
fibroblast | 4 studies | 19% ± 4% | |
ciliated cell | 4 studies | 22% ± 4% | |
interneuron | 4 studies | 49% ± 22% | |
GABAergic interneuron | 3 studies | 23% ± 2% | |
epithelial cell | 3 studies | 30% ± 6% | |
retinal cone cell | 3 studies | 18% ± 3% | |
dendritic cell | 3 studies | 19% ± 3% | |
endothelial cell of lymphatic vessel | 3 studies | 17% ± 1% | |
adipocyte | 3 studies | 18% ± 3% | |
neuron | 3 studies | 26% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 372.76 | 1445 / 1445 | 100% | 3.05 | 183 / 183 |
brain | 100% | 415.53 | 2640 / 2642 | 100% | 3.22 | 705 / 705 |
ovary | 100% | 440.58 | 180 / 180 | 100% | 3.03 | 429 / 430 |
prostate | 100% | 399.04 | 245 / 245 | 99% | 2.54 | 499 / 502 |
lung | 100% | 428.07 | 577 / 578 | 99% | 2.72 | 1147 / 1155 |
breast | 100% | 563.91 | 459 / 459 | 99% | 2.86 | 1108 / 1118 |
thymus | 100% | 491.47 | 653 / 653 | 99% | 3.48 | 598 / 605 |
uterus | 100% | 467.91 | 170 / 170 | 98% | 2.89 | 452 / 459 |
adrenal gland | 100% | 425.86 | 258 / 258 | 98% | 3.19 | 226 / 230 |
stomach | 100% | 293.26 | 359 / 359 | 97% | 2.60 | 278 / 286 |
intestine | 100% | 371.35 | 966 / 966 | 97% | 2.53 | 511 / 527 |
bladder | 100% | 430.29 | 21 / 21 | 97% | 2.65 | 487 / 504 |
kidney | 100% | 431.92 | 89 / 89 | 96% | 2.29 | 868 / 901 |
pancreas | 100% | 212.23 | 328 / 328 | 96% | 2.20 | 171 / 178 |
skin | 100% | 419.99 | 1807 / 1809 | 90% | 2.09 | 423 / 472 |
liver | 100% | 229.88 | 226 / 226 | 80% | 1.32 | 326 / 406 |
adipose | 100% | 537.43 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 521.96 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 2.50 | 29 / 29 |
spleen | 100% | 383.44 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 1.59 | 1 / 1 |
muscle | 100% | 392.51 | 802 / 803 | 0% | 0 | 0 / 0 |
heart | 99% | 310.07 | 853 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 2.42 | 44 / 45 |
eye | 0% | 0 | 0 / 0 | 64% | 1.24 | 51 / 80 |
peripheral blood | 50% | 208.82 | 466 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0031145 | Biological process | anaphase-promoting complex-dependent catabolic process |
GO_0070936 | Biological process | protein K48-linked ubiquitination |
GO_0070979 | Biological process | protein K11-linked ubiquitination |
GO_0051301 | Biological process | cell division |
GO_0051445 | Biological process | regulation of meiotic cell cycle |
GO_0007346 | Biological process | regulation of mitotic cell cycle |
GO_0005680 | Cellular component | anaphase-promoting complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005515 | Molecular function | protein binding |
Gene name | ANAPC10 |
Protein name | Anaphase-promoting complex subunit 10 (APC10) (Cyclosome subunit 10) Anaphase-promoting complex subunit 10 |
Synonyms | APC10 |
Description | FUNCTION: Component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle. The APC/C complex acts by mediating ubiquitination and subsequent degradation of target proteins: it mainly mediates the formation of 'Lys-11'-linked polyubiquitin chains and, to a lower extent, the formation of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains. . |
Accessions | ENST00000512680.5 D6RA92 ENST00000451299.6 ENST00000613466.4 Q9UM13 ENST00000502847.1 D6RD74 D6R9Q5 ENST00000507656.6 ENST00000504721.5 ENST00000309439.9 D6RB36 ENST00000641499.1 ENST00000514390.5 ENST00000513054.5 A0A286YEY6 |